Factors to Consider for Frontline Treatment of Transplant-Ineligible MM
Caitlin Costello, MD, describes how to determine if a patient with MM is transplant-ineligible, and some factors to take into consideration when choosing a treatment regimen.
EP: 1.Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM
EP: 2.Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM
EP: 3.Determining the Right Patients with NDMM for Autologous Stem Cell Transplant
EP: 4.Duration of Therapy and Maintenance Treatment in Transplant-Eligible NDMM
EP: 5.Treating Patients with High-Risk NDMM
Now Viewing
EP: 6.Factors to Consider for Frontline Treatment of Transplant-Ineligible MM
EP: 7.Transplant-Ineligible Multiple Myeloma: The MAIA and SWOG 0777 Trials
EP: 8.Transplant-Ineligible Multiple Myeloma: The ENDURANCE Study
EP: 9.Role of Triplet Therapy in Frail Patients with Transplant-Ineligible NDMM
EP: 10.Maintenance Therapy in Transplant-Ineligible NDMM
EP: 11.Available Treatment Options for Relapsed/Refractory Multiple Myeloma
EP: 12.Bispecific Antibodies in the Treatment of R/R MM
EP: 13.CAR-T Therapy in R/R MM Treatment
EP: 14.Choosing a Bispecific Antibody for Treatment of R/R MM After Prior BCMA Therapy
EP: 15.Sequencing Therapies in Patients with R/R MM
EP: 16.Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022
EP: 17.Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
